



A service of the National Library of Medicine
and the National Institutes of Health

[My NCBI](#)
[\[Sign In\]](#) [\[Reg\]](#)

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Bo.

Search for

Limits History Details

About Entrez

[Text Version](#)

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Search	Most Recent Queries	Time	Result
	#14 Search epha2 and antigen and CTL	14:04:06	1
	#13 Search epha2 and peptide and immunogenic	14:04:00	1
	#24 Search ephrinA2 and peptide	14:03:21	4
	#23 Search ephrin and peptide	14:03:09	778
	#22 Search ephrin and epitope	14:02:33	4
	#21 Search epa2	14:02:08	1
	#19 Search eck and epitope	13:58:41	4
	#18 Search epha2 and epitope	13:57:55	6
	#16 Search epha2 and CTL	13:54:54	2
	#12 Search epha2 and peptide	13:47:13	80
	#11 Search epha2	13:47:03	155
	#10 Search #5 and CD8	13:46:24	1
	#7 Search epha and peptide and t cell	13:42:41	5
	#6 Search epha and peptide and epitope	13:42:06	1
	#5 Search epha and peptide	13:41:43	76
	#4 Search epha and immunogenic peptide	13:41:37	0
	#3 Search epha	13:41:22	118
	#2 Search epha and MHC 1	13:41:16	0
	#1 Search epha and t epitope	13:41:09	0

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 2 2006 08:29:36

WEST Search History

[Hide Items](#) | [Restore](#) | [Clear](#) | [Cancel](#)

DATE: Friday, October 06, 2006

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L12	L11 and CTL	5
<input type="checkbox"/>	L11	L8 and (immunogenic peptide)	13
<input type="checkbox"/>	L10	L9 and CTL	29
<input type="checkbox"/>	L9	L8 and peptide	124
<input type="checkbox"/>	L8	ephrinA2 or epha2 and epitope	131
<input type="checkbox"/>	L7	L6 and immunogen	16
<input type="checkbox"/>	L6	L5 and epitope	35
<input type="checkbox"/>	L5	L4 and CTL	37
<input type="checkbox"/>	L4	L3 and HLA	237
<input type="checkbox"/>	L3	L1 and peptide	1274
<input type="checkbox"/>	L2	L1 and peptide or epitope	66196
<input type="checkbox"/>	L1	ephrinA2 or epha2 or eck	10572

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTALAB1643

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5 MAY 11 KOREAPAT updates resume
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in INPADOC
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and display fields
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 13 JUL 14 FSTA enhanced with Japanese patents
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 17 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 19 SEP 21 CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 20 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 23 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:00:16 ON 06 OCT 2006

=> file caplus, bioeng, biotechno, biotechds, esbiobase
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 15:00:56 ON 06 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOENG' ENTERED AT 15:00:56 ON 06 OCT 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 15:00:56 ON 06 OCT 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHDS' ENTERED AT 15:00:56 ON 06 OCT 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'ESBIOBASE' ENTERED AT 15:00:56 ON 06 OCT 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

```
=> S (T CELL EPITOPE) OR (T EPITOPE)
      3 FILES SEARCHED...
L1          9390 (T CELL EPITOPE) OR (T EPITOPE)
```

=> s epha2 and L1
L2 5 EPHA2 AND L1

```
=> duplicate remove l2
DUPLICATE PREFERENCE IS 'CAPLUS, BIOTECHHDS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L2
L3          4 DUPLICATE REMOVE L2 (1 DUPLICATE REMOVED)
```

=> d 13 bib abs 1-4

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:333546 CAPLUS
DN 144:329777
TI Epitope variants for enhancing glioma-specific cytotoxic T cell response
IN Storkus, Walter J.; Sato, Hidemitsu; Okada, Hideho; Eguchi, Junichi
PA University of Pittsburgh of the Commonwealth System of Higher Education,
USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006034334	A2	20060330	WO 2005-US33794	20050921
	WO 2006034334	A3	20060914		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRAI US 2004-611797P P 20040921

AB The authors disclose peptide variants derived from the interleukin-13 receptor α 2, which exhibit increased affinity for HLA-A2 and elicit an enhanced cytotoxic T lymphocyte (CTL) response. The peptide variants can be used as a vaccine for glioma and can be formulated into compns. for medical or veterinary use. In addition, the authors also disclose a peptide derived from the EphA2 tyrosine kinase receptor which may be used for therapy of glioma.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:120967 CAPLUS
DN 142:217364
TI Human EphA2 protein T cell epitope agonists for ELISPOT assay and as vaccines against tumor overexpressing EphA2
IN Storkus, Walter J.; Kinch, Michael S.
PA University of Pittsburgh-of the Commonwealth System of Higher Education, USA; Medimmune, Inc.
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012350	A2	20050210	WO 2004-US23931	20040722
	WO 2005012350	A3	20050714		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004261603	A1	20050210	AU 2004-261603	20040722
	CA 2533789	AA	20050210	CA 2004-2533789	20040722
	US 2005048550	A1	20050303	US 2004-897711	20040722
	EP 1651671	A2	20060503	EP 2004-779136	20040722
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	US 2006019899	A1	20060126	US 2005-233796	20050923
PRAI	US 2003-491046P	P	20030730		
	US 2004-897711	A1	20040722		
	WO 2004-US23931	W	20040722		

AB EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivs. thereof. The EphA2 T-cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma. The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:385550 CAPLUS
 DN 142:428349
 TI Vaccination with EphA2-derived T cell-
 epitopes promotes immunity against both EphA2-expressing
 and EphA2-negative tumors
 AU Hatano, Manabu; Kuwashima, Naruo; Tatsumi, Tomohide; Dusak, Jill E.;
 Nishimura, Fumihiko; Reilly, Karlyne M.; Storkus, Walter J.; Okada, Hideho
 CS Department of Neurological Surgery, University of Pittsburgh School of
 Medicine, Pittsburgh, PA, 15213, USA
 SO Journal of Translational Medicine (2004), 2, No pp. given
 CODEN: JTMOBV; ISSN: 1479-5876
 URL: <http://www.translational-medicine.com/content/pdf/1479-5876-2-40.pdf>
 PB BioMed Central Ltd.
 DT Journal; (online computer file)
 LA English
 AB Background: A novel tyrosine kinase receptor EphA2 is expressed
 at high levels in advanced and metastatic cancers. The authors examined
 whether vaccinations with synthetic mouse EphA2 (mEphA2)-derived
 peptides that serve as T cell epitopes could
 induce protective and therapeutic anti-tumor immunity. Methods: C57BL/6
 mice received s.c. vaccinations with bone marrow-derived dendritic cells
 (DCs) pulsed with synthetic peptides recognized by CD8+ (mEphA2671-679,
 mEphA2682-689) and CD4+ (mEphA230-44) T cells. Splenocytes (SPCs) were
 harvested from primed mice to assess the induction of cytotoxic T
 lymphocyte (CTL) responses against syngeneic glioma, sarcoma and melanoma
 cell lines. The ability of these vaccines to prevent or treat tumor (s.c.)
 injected MCA205 sarcoma or B16 melanoma; i.v. injected B16-BL6)
 establishment/progression was then assessed. Results: Immunization of
 C57BL/6 mice with mEphA2-derived peptides induced specific CTL responses
 in SPCs. Vaccination with mEphA2 peptides, but not control ovalbumin
 (OVA) peptides, prevented the establishment or prevented the growth of
 EphA2+ or EphA2-neg. syngeneic tumors in both s.c. and
 lung metastasis models. Conclusions: These data indicate that mEphA2 can
 serve as an attractive target against which to direct anti-tumor immunity.
 The ability of mEphA2 vaccines to impact EphA2-neg. tumors such
 as the B16 melanoma may suggest that such beneficial immunity may be
 directed against alternative EphA2+ target cells, such as the
 tumor-associated vascular endothelial cells.

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
 AN 2003:837593 CAPLUS
 DN 139:322275
 TI Peptide T epitopes of the EphA2 antigen for
 antitumor immunotherapy
 IN Kosmatopoulos, Kostas; Alves, Pedro
 PA Institut National de la Sante et de la Recherche Medicale INSERM, Fr.;
 Institut Gustave Roussy
 SO Fr. Demande, 22 pp.
 CODEN: FRXXBL

DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2838742	A1	20031024	FR 2002-5048	20020423
	FR 2838742	B1	20040709		
	CA 2482930	AA	20031106	CA 2003-2482930	20030423
	WO 2003091383	A2	20031106	WO 2003-FR1280	20030423
	WO 2003091383	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003262810 A1 20031110 AU 2003-262810 20030423
 EP 1497417 A2 20050119 EP 2003-740654 20030423
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 US 2006034856 A1 20060216 US 2005-511273 20050627
 PRAI FR 2002-5048 A 20020423
 WO 2003-FR1280 W 20030423
 AB The invention discloses peptides constituting EphA2 antigen
 T epitopes, presented by MHC I. The peptides are useful
 in particular for antitumor immunotherapy.
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (epha2 or ephrin) and peptide and immunogen
 L4 0 (EPHA2 OR EPHRIN) AND PEPTIDE AND IMMUNOGEND
 => s epha2 and peptide
 L5 46 EPHA2 AND PEPTIDE
 => duplicate remove 15
 DUPLICATE PREFERENCE IS 'CAPLUS, BIOTECHNO, BIOTECHDS, ESBIOBASE'
 KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
 PROCESSING COMPLETED FOR L5
 L6 31 DUPLICATE REMOVE L5 (15 DUPLICATES REMOVED)
 => s HLA and L6
 L7 9 HLA AND L6
 => duplicate remove L7
 PROCESSING COMPLETED FOR L7
 L8 9 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
 => d 18 bib abs 1-9
 L8 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:333546 CAPLUS
 DN 144:329777
 TI Epitope variants for enhancing glioma-specific cytotoxic T cell response
 IN Storkus, Walter J.; Sato, Hidemitsu; Okada, Hideho; Eguchi, Junichi
 PA University of Pittsburgh of the Commonwealth System of Higher Education,
 USA
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006034334	A2	20060330	WO 2005-US33794	20050921
WO 2006034334	A3	20060914		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,			

NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
 YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRAI US 2004-611797P P 20040921

AB The authors disclose peptide variants derived from the interleukin-13 receptor α_2 , which exhibit increased affinity for HLA-A2 and elicit an enhanced cytotoxic T lymphocyte (CTL) response. The peptide variants can be used as a vaccine for glioma and can be formulated into compns. for medical or veterinary use. In addition, the authors also disclose a peptide derived from the EphA2 tyrosine kinase receptor which may be used for therapy of glioma.

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:120967 CAPLUS

DN 142:217364

TI Human EphA2 protein T cell epitope agonists for ELISPOT assay and as vaccines against tumor overexpressing EphA2

IN Storkus, Walter J.; Kinch, Michael S.

PA University of Pittsburgh-of the Commonwealth System of Higher Education, USA; Medimmune, Inc.

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012350	A2	20050210	WO 2004-US23931	20040722
	WO 2005012350	A3	20050714		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004261603	A1	20050210	AU 2004-261603	20040722
	CA 2533789	AA	20050210	CA 2004-2533789	20040722
	US 2005048550	A1	20050303	US 2004-897711	20040722
	EP 1651671	A2	20060503	EP 2004-779136	20040722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2006019899	A1	20060126	US 2005-233796	20050923
PRAI	US 2003-491046P	P	20030730		
	US 2004-897711	A1	20040722		
	WO 2004-US23931	W	20040722		

AB EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivs. thereof. The EphA2 T-cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a

treatment for cancers that overexpress EphA2, such as renal cell carcinoma. The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1020555 CAPLUS
DN 143:320266
TI Genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ
IN Ueda, Minoru; Yamada, Yoichi
PA Hitachi Medical Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 246 pp.
CODEN: JKXXAF

DT Patent
LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI JP 2005253442	A2	20050922	JP 2004-111582	20040309
PRAI JP 2004-111582		20040309		

AB The present invention relates to a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells, as well as a method for regenerating tooth germ using these genes. According to the present invention, the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cell were revealed, and a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells was identified. By utilizing the groups of the genes of the present invention together with the dental pulp stem cells and mesenchymal stem cells, hard tissue such as tooth germ, dental pulp, dentin or bone can be regenerated. The present inventors investigated the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cells, resp. At first, the present inventors confirmed the differential expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1 (DMP 1), Dentin phosphosialoprotein (DSPP) using by real time reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from primary cultures. The number of genes in hDPSCs(I) that were up-regulated by >2-fold, compared to hMSCs, was 614 (Table, IV). On the other hand, the number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III, IV).

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1201395 CAPLUS
DN 144:189389
TI EphA2 as a glioma-associated antigen: A novel target for glioma vaccines
AU Hatano, Manabu; Eguchi, Junichi; Tatsumi, Tomohide; Kuwashima, Naruo; Dusak, Jill E.; Kinch, Michel S.; Pollack, Ian F.; Hamilton, Ronald L.; Storkus, Walter J.; Okada, Hideho
CS Department of Neurological Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA
SO Neoplasia (Ann Arbor, MI, United States) (2005), 7(8), 717-722
CODEN: NEOPFL; ISSN: 1522-8002
PB Neoplasia Press Inc.
DT Journal
LA English
AB EphA2 is a receptor tyrosine kinase and is frequently overexpressed in a wide array of advanced cancers. We demonstrate in the current study that the EphA2 protein is restrictedly expressed in primary glioblastoma multiforme and anaplastic astrocytoma tissues in

comparison to normal brain tissues. To evaluate the possibility of targeting EphA2 in glioma vaccine strategies, we stimulated human leukocyte antigen (HLA) A2+ peripheral blood mononuclear cells (PBMCs) obtained from healthy donors and glioma patients with autologous dendritic cells (DCs) loaded with synthetic EphA2883-891 peptide (TLADFDPPRV), which has previously been reported to induce interferon- γ in HLA-A2+ PBMCs. Stimulated PBMCs demonstrated antigen-specific cytotoxic T lymphocyte (CTL) responses as detected by specific lysis of T2 cells loaded with the EphA2883 peptide as well as HLA-A2+ glioma cells, SNB19 and U251, that express EphA2. Furthermore, in vivo immunization of HLA-A2 transgenic HHD mice with the EphA2883-891 peptide resulted in the development of an epitope-specific CTL response in splenocytes, despite the fact that EphA2883-891 is an autoantigen in these mice. Taken together, these data suggest that EphA2883-891 may be an attractive antigen epitope for molecularly targeted glioma vaccines.

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:308529 CAPLUS
DN 140:333599
TI Gene expression profile of human and mouse genes in atopic dermatitis and psoriasis patients and its use for diagnosis, therapy, and drug screening
IN Itoh, Mikito; Ogawa, Kaoru; Shinagawa, Akira; Sudo, Hajime; Ogawa, Hideoki; Ra, Chisei; Mitsuishi, Kouichi
PA Genox Research, Inc., Japan; Juntendo University
SO PCT Int. Appl., 611 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031386	A1	20040415	WO 2003-JP9808	20030801
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003252326	A1	20040423	AU 2003-252326	20030801
PRAI	JP 2002-229318	A	20020806		
	JP 2003-136543	A	20030514		
	WO 2003-JP9808	W	20030801		

AB This invention provides gene expression profile between a rash site and a no-rash site in a patient with atopic dermatitis or a patient with psoriasis. The invention also provides gene expression profile between a no-rash site in such a disease and a normal subject. Animal models, particularly mouse for those diseases are also claimed. The gene expression profile provided in this invention can be used for diagnosis, therapy, and drug screening for atopic dermatitis and psoriasis.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:837593 CAPLUS
DN 139:322275
TI Peptide T epitopes of the EphA2 antigen for antitumor immunotherapy

IN Kosmatopoulos, Kostas; Alves, Pedro
 PA Institut National de la Sante et de la Recherche Medicale INSERM, Fr.;
 Institut Gustave Roussy
 SO Fr. Demande, 22 pp.
 CODEN: FRXXBL
 DT Patent
 LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2838742	A1	20031024	FR 2002-5048	20020423
	FR 2838742	B1	20040709		
	CA 2482930	AA	20031106	CA 2003-2482930	20030423
	WO 2003091383	A2	20031106	WO 2003-FR1280	20030423
	WO 2003091383	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003262810	A1	20031110	AU 2003-262810	20030423
	EP 1497417	A2	20050119	EP 2003-740654	20030423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006034856	A1	20060216	US 2005-511273	20050627
PRAI	FR 2002-5048	A	20020423		
	WO 2003-FR1280	W	20030423		

AB The invention discloses peptides constituting EphA2 antigen T epitopes, presented by MHC I. The peptides are useful in particular for antitumor immunotherapy.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:982383 CAPLUS
 DN 140:75821
 TI EphA2 as Target of Anticancer Immunotherapy: Identification of HLA-A*0201-Restricted Epitopes
 AU Alves, Pedro M. S.; Faure, Olivier; Graff-Dubois, Stephanie; Gross, David-Alexandre; Cornet, Sebastien; Chouaib, Salem; Miconnet, Isabelle; Lemonnier, Francois A.; Kosmatopoulos, Kostas
 CS INSERM487, Institut Gustave Roussy, Villejuif, Fr.
 SO Cancer Research (2003), 63(23), 8476-8480
 CODEN: CNREA8; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal
 LA English
 AB EphA2 (Eck) is a tyrosine kinase receptor that is overexpressed in several human cancers such as breast, colon, lung, prostate, gastric carcinoma, and metastatic melanoma but not in nonmalignant counterparts. To validate EphA2 as a tumor antigen recognized by CD8+ T lymphocytes, we used reverse immunol. approach to identify HLA -A*0201-restricted epitopes. Peptides bearing the HLA -A*0201-specific anchor motifs were analyzed for their capacity to bind and stabilize the HLA-A*0201 mols. Two peptides, EphA258 and EphA2550, with a high affinity for HLA-A*0201 were selected. Both peptides were immunogenic in the HLA -A*0201-transgenic HHD mice. Interestingly, peptide-specific murine CTLs cell lines responded to COS-7 cells coexpressing HLA

-A*0201 and EphA2 and to EphA2-pos. human tumor cells of various origin (renal cell, lung, and colon carcinoma and sarcoma). This demonstrates that EphA258 and EphA2550 are naturally processed from endogenous EphA2. In addition, EphA258 and EphA2550 stimulated specific CD8+ T cells from healthy donor peripheral blood mononuclear cells. These T cells recognized EphA2-pos. human tumor cells in an HLA-A*0201-restricted manner. Interestingly, EphA2-specific CD8+ T cells were detected in the peripheral blood mononuclear cells of prostate cancer patients. These results show for the first time that EphA2 is a tumor rejection antigen and lead us to propose EphA258 and EphA2550 peptides for a broad-spectrum-tumor immunotherapy.

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:613807 CAPLUS
DN 139:275676
TI Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma
AU Tatsumi, Tomohide; Herrem, Christopher J.; Olson, Walter C.; Finke, James H.; Bukowski, Ronald M.; Kinch, Michael S.; Ranieri, Elena; Storkus, Walter J.
CS Departments of Surgery and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA
SO Cancer Research (2003), 63(15), 4481-4489
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB The authors have evaluated CD8+ and CD4+ T-cell responses against a new tumor-associated antigen, the receptor tyrosine kinase EphA2, which is broadly expressed in diverse cancer histologies and is frequently overexpressed in advanced stage/metastatic disease. They report herein that EphA2 is overexpressed in renal cell carcinoma (RCC) cell lines and clin. specimens of RCC, and find that the highest levels of EphA2 are consistently found in the most advanced stages of the disease. The authors identified and synthesized 5 putative HLA class I-binding and 3 class II-binding peptides derived from EphA2 that might serve as targets for immune reactivity. Each peptide induced specific, tumor-reactive CD8+ or CD4+T-cell responses as measured using IFN- γ enzyme-linked immunospot assays. The EphA2 peptides elicited relatively weak responses from CD8+ T cells derived from normal healthy volunteers or from RCC patients with active disease. In marked contrast, immune reactivity to EphA2-derived epitopes was greatly enhanced in CD8+ T cells that had been isolated from patients who were rendered disease-free, after surgery. Furthermore, enzyme-linked immunospot analyses demonstrated prominent EphA2-restricted T-helper 1-type CD4+ T cell activity in patients with early stage disease, whereas T-helper 2-type and T regulatory-type responses predominated in patients with more advanced forms of RCC. Thus, the immune system of cancer patients actively monitors EphA2-derived epitopes, and the magnitude and character of T-cell responses to EphA2 epitopes may convey much-needed predictive information about disease stage and outcome.

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:937303 CAPLUS
DN 138:20443
TI Endocrine disruptor screening using DNA chips of endocrine disruptor-responsive genes
IN Kondo, Akihiro; Takeda, Takeshi; Mizutani, Shigetoshi; Tsujimoto,

PA Yoshimasa; Takashima, Ryokichi; Enoki, Yuki; Kato, Ikunoshin
Takara Bio Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 386 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002355079	A2	20021210	JP 2002-69354	20020313
PRAI	JP 2001-73183	A	20010314		
	JP 2001-74993	A	20010315		
	JP 2001-102519	A	20010330		

AB A method and kit for detecting endocrine-disrupting chems. using DNA microarrays are claimed. The method comprises preparing a nucleic acid sample containing mRNAs or cDNAs originating in cells, tissues, or organisms which have been brought into contact with a sample containing the endocrine disruptor. The nucleic acid sample is hybridized with DNA microarrays having genes affected by the endocrine disruptor or DNA fragments originating in these genes have been fixed. The results obtained are then compared with the results obtained with the control sample to select the gene affected by the endocrine disruptor. Genes whose expression is altered by tri-Bu tin, 4-octaphenol, 4-nonylphenol, di-N-Bu phthalate, dichlorohexyl phthalate, octachlorostyrene, benzophenone, diethylhexyl phthalate, diethylstilbestrol (DES), and 17-β estradiol (E2), were found in mice by DNA chip anal.

=> display history
ENTER (BRIEF), FULL, OR NOFILE:full
ENTER (L1-), L#, OR ?:11

(FILE 'CAPLUS, BIOENG, BIOTECHNO, BIOTECHDS, ESBIOSBASE' ENTERED AT
15:00:56 ON 06 OCT 2006)
L1 9390 SEA ABB=ON PLU=ON (T CELL EPITOPE) OR (T EPITOPE)

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Oct 2006 VOL 145 ISS 16
FILE LAST UPDATED: 5 Oct 2006 (20061005/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE BIOENG
FILE LAST UPDATED: 16 AUG 2006 <20060816/UP>
FILE COVERS 1982 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN

THE BASIC INDEX <<<

FILE BIOTECHNO
FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>
FILE COVERS 1980 TO 2003.

>>> BIOTECHNO IS NO LONGER BEING UPDATED AS OF 2004 <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
/CT AND BASIC INDEX <<<

FILE BIOTECHDS
FILE LAST UPDATED: 4 OCT 2006 <20061004/UP>
FILE COVERS 1982 TO DATE

>>> USE OF THIS FILE IS LIMITED TO BIOTECH SUBSCRIBERS <<<

FILE ESBIOBASE
FILE LAST UPDATED: 3 OCT 2006 <20061003/UP>
FILE COVERS 1994 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
/CC, /ORGN, AND /ST <<<